← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 1, 1998First marketed drug
Feb 12, 2004First NDA
Feb 12, 2004Last known activity
Oct 1, 2011
Acquired by Eli Lilly on Nov 24, 2008
Timeline
Drugs by trial phase (30 distinct, 59 trials)
Phase 3 (17 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Approved for
Studied for
- Adenocarcinoma
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Small Cell
- Carcinoma, Squamous Cell
- Colonic Neoplasms
- Colorectal Neoplasms
- Disease Progression
- Fallopian Tube Neoplasms
- Glioblastoma
- Head and Neck Neoplasms
- Hodgkin Disease
- Leiomyosarcoma
- Leukemia
- Leukemia, Myeloid
- Lung Neoplasms
- Lymphoma
- Melanoma
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Squamous Cell
- Neuroectodermal Tumors
- Neuroectodermal Tumors, Primitive
- Neuroectodermal Tumors, Primitive, Peripheral
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Peritoneal Neoplasms
- Prostatic Neoplasms
- Rectal Neoplasms
- Rhabdomyosarcoma
- Sarcoma
- Sarcoma, Ewing
- Sarcoma, Synovial
- Small Cell Lung Carcinoma
- Squamous Cell Carcinoma of Head and Neck
- Stomach Neoplasms
- Urinary Bladder Neoplasms
- Uterine Cervical Neoplasms
Marketed drugs (1)
Recent trials (50)
- NCT00957853CollaboratorPhase 2Oct 1, 2011
- NCT00816959CollaboratorPhase 3Jul 1, 2011
- NCT00797472CollaboratorPhase 2Jul 1, 2011
- NCT01263782CollaboratorPhase 2May 1, 2011
- NCT01232452CollaboratorPhase 2Apr 1, 2011
- NCT01168973CollaboratorPhase 3Dec 1, 2010
- NCT01183780CollaboratorPhase 3Dec 1, 2010
- NCT00895180CollaboratorPhase 2Jul 1, 2010
- NCT01137006Study directorPhase 1Jun 1, 2010
- NCT01137006Lead sponsorPhase 1Jun 1, 2010
- NCT00954876CollaboratorPhase 2Aug 1, 2009
- NCT00887926Study directorPhase 1Jun 1, 2009
- NCT00887926Lead sponsorPhase 1Jun 1, 2009
- NCT00845039Lead sponsorPhase 2May 1, 2009
- NCT00845039Study directorPhase 2May 1, 2009
Details
- Founded
- Bridgewater, NJ, US Jan 1, 1984
- First NDA
- Feb 12, 2004
- Last known activity
- Oct 1, 2011
Designations held
- Orphan drug
- Accelerated approval
Notes
Acquired by Eli Lilly